Remove Acquisition Remove Funding Remove Layoffs Remove Pricing
article thumbnail

Sell when growth is high, even if cash flow is low.

Berkonomics

Dave’s note: Our guest author this week is John Huston, founder of the 300+ member Ohio TechAngel Funds and a past Chairman of both the Angel Capital Association and the Angel Resource Institute. . Until it is reached, survival still hinges on the kindness of outside funding sources. By John Huston.

Layoffs 120
article thumbnail

10 Strategies For Success Long-Term As Well As Today

Startup Professionals Musings

In the short term you need customers to find you at any price, and in the longer term you need revenue, profit, and return loyalty. Distinguish growth opportunities from survival efforts, and make sure they are adequately funded, rewarded, and measured. Constantly scan the horizon for growth opportunities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More

Xconomy

military’s high-tech think tank DARPA described Safe Genes, a new program to fund safety measures that can be built into genome editing technology or counter its potential wayward effects. The funding could be as much as $100 million, and the first grants will be announced in 2017. PRICE FIGHTS. —The U.S.

article thumbnail

Interview with Greg Martin, LiquidStock

socalTECH

Our interview today is with Greg Martin , co-founder of LiquidStock (www.liquidstock.com), an investment fund which offers up a way for employees of private companies to exercise their stock options before an IPO or acquisition. Greg Martin: I raised a fund called LiquidStock, with three partners. Tell us what you're up to now?

Startup 113
article thumbnail

Biotech Roundup: Moonshots, Pink Slips, Gilead, Brexit & More

Xconomy

At the gathering, Biden took verbal shots at scofflaw cancer researchers and at drug prices, while the FDA said it would take a shot at restructuring the way it evaluates oncology products. Gilead Sciences has been a target of drug-price criticism for its hepatitis C treatments, but it dialed back the price of its new one.